Research, Collaboration and Licensing Agreements (Tables)

12 Months Ended

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Revenue Recognized from Strategic Partnerships

Revenue recognized from the Company’s strategic partnerships is summarized as follows:

	Year ended December 31,
	2021		2020		2019
BeiGene:
Milestone revenue	$	8,000	$	15,000	$	—
Recognition of upfront fee	—		—		3,530
Janssen:
Milestone revenue	8,000		—		—
Iconic:
Partner revenue	5,000		4,000		—
Milestone revenue	—		—		1,000
BMS:
Upfront fee relating to amendment	—		12,000		—
Option exercise fee	—		—		7,500
Merck:
Milestone revenue	—		—		2,000
Lilly:
Milestone revenue	—		—		8,000
Daiichi Sankyo:
Commercial license option fee	—		—		3,500
Research support payments and other payments	5,680		7,951		4,014
	$	26,680	$	38,951	$	29,544